2028年将领导全球药物开发的细胞计划,目标是13个新的药物应用。 Celltrion plans to lead global drug development by 2028, targeting 13 new drug applications.

韩国生物制药公司Celltrion概述了到2028年成为全球药物开发领先企业的计划,目的是提交13份调查性新药物申请。 South Korean biopharmaceutical firm Celltrion outlined plans to become a global leader in drug development by 2028, aiming to submit 13 Investigational New Drug applications. 该公司的战略侧重于下一代抗体药物合体和多种特定抗体,主要发展包括用于固态癌症和双荷载ADC的CT-P70和CT-P71。 The company's strategy focuses on next-generation antibody drug conjugates and multispecific antibodies, with key developments including CT-P70 and CT-P71 for solid cancers and dual-payload ADCs. Celltrion还寻求从事合同开发和制造业务。 Celltrion also seeks to enter the contract development and manufacturing business.